
$4.8B+22% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Revenue reached $4.8B in 2025, compounding +29% a year since 2022 though the pace has cooled. The trailing twelve months are already running at $5.4B, ahead of the last full year.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
$-161MFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→The company lost $161M in 2025, more than the $13M it lost the year before. The losses are widening - check the Health chapter for how long the cash lasts.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
+21.7%revenue growth, FY 2025
→Revenue grew +22% in 2025 against a five-year average of +42%.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
$1.3B+16% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Free cash flow was $1.3B in 2025, compounding +23% a year since 2022. That is the most cash the business has ever thrown off in a year. The trailing twelve months stand at $1.6B.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
→Of $4.8B in 2025 sales, nothing survives to the bottom line - the journey ends $161M underwater.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→27 cents of every sales dollar became free cash in 2025, down 4 points since 2022.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
◌ 2026 = trailing twelve months to the latest filed quarter (2026-07-31), not a full fiscal year
→The biggest claim on each sales dollar is research and development, at 29% of revenue (stock compensation 23%, capital spending 6%).
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
◌ 2026 = trailing twelve months to the latest filed quarter (2026-07-31), not a full fiscal year
→Operating margin widened 2 points to -6% since 2022. The bottom line is still negative: costs below the operating line eat what is left.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
◌ 2026 = trailing twelve months to the latest filed quarter (2026-07-31), not a full fiscal year
→ROE of 1% sits well above ROCE of -4%. A meaningful share of the shareholder return is manufactured with leverage rather than operations.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
1152.5xP/E today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→At 40.4x sales, the market is paying +707% more than CRWD's own 7-year median of 5.0x. Expectations are elevated, so more has to go right to justify the price.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
0.7%FCF yield today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→Every dollar of market value currently buys 0.7% of annual free cash flow, less than its 7-year median of 4.8% - you are paying up for the same cash.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
→The company holds $5.0B in cash against $746M of debt - a net-cash balance sheet, which means a bad year is an inconvenience rather than a threat.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
→The company's own capital grew from $2.3B in 2023 to $5.1B (+121%). The business is building book value rather than consuming it.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
→CRWD returned no cash to shareholders in the latest filed year: everything is being retained or reinvested.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
→The share count grew 2.4% in 2025, averaging 2.4% a year over three years. Your slice of the company shrinks by that much each year unless earnings grow faster.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
→CRWD's return on capital is negative at -4.2% in 2025. The capital in the business is not yet earning anything back.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
→CRWD issued +69% more shares from 2019 to 2025, but revenue per share still rose +491%. The dilution bought more growth than it cost existing holders.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31
→Insiders sold $127M on the open market and bought nothing. Many sales are pre-scheduled diversification rather than a view on the price.
Source: SEC EDGAR (XBRL company facts) · as at 2026-07-31